Molecular Docking-Aided Identification of Natural Bioactive Molecules as Potential Cancer Cell Proliferation Inhibitors
Molecular Docking as Cancer Cell Inhibitors
DOI:
https://doi.org/10.54393/fbt.v4i02.105Keywords:
Cell Proliferation Inhibitors, Sesquiterpene Lactones, Molecular DockingAbstract
Cancer is the second leading cause of death worldwide. Uncontrolled proliferation of cells is a hallmark of cancer development and progression. Ki-67 (a marker of proliferation Kiel-67) and Proliferating Cell Nuclear Antigen (PCNA) are two major proliferations, diagnostic and prognostic biomarkers as these are over expressed in cancerous cells. Pharmacological inhibition of Ki-67 and PCNA could effectively inhibit the growth of cancer cells. Objective: To identify Sesquiterpene Lactones (SLs) as potential inhibitors of Ki-67 and PCNA to reduce cancer burden. Methods: The inhibitory potential of SLs, namely sulfocostunolide A, sulfocostunolide B, ilicol, eucalyptone, and ascleposide E, were investigated using Molecular Docking (MD) analysis. MD analysis and visualization of ligand-protein complexes were performed using softwares such as MGL tools, BIOVIA Discovery Studio visualizer and LigPlot plus. Additionally, drug likeness and pharmacokinetic properties of SLs were assessed via pkCSM and ADMET analysis. Results: Results showed that eucalyptone with binding energy of -8.1 kcal/mol with Ki-67 while sulfocostunolide B with -6.4 kcal/mol binding energy with PCNA are the most potent proliferative inhibitors of Ki-67 and PCNA. ADMET properties, MD studies and toxicity prediction shows that current investigated ligands bind effectively with Ki-67 and PCNA without showing any toxicity. Conclusions: Current study concludes that eucalyptone with Ki-67 and sulfocostunolide B with PCNA made stable complexes and can be considered as novel inhibitors. In addition to that, these suggested ligands have also shown effective drug likeness and ADMET profile. Further, in-vitro and in-vivo studies are required to validate these findings.
References
Xu C, Sun G, Yuan G, Wang R, Sun X. Effects of platycodin D on proliferation, apoptosis and PI3K/Akt signal pathway of human glioma U251 cells. Molecules. 2014 Dec; 19(12): 21411-23. doi: 10.3390/molecules191221411.
Chakraborty S and Rahman T. The difficulties in cancer treatment. Ecancer Medical Science. 2012 Nov; 6: ed16: doi: 10.3332/ecancer.2012.ed16.
Saini A, Kumar M, Bhatt S, Saini V, Malik A. Cancer causes and treatments. International Journal of Pharmaceutical Sciences and Research. 2020 Jul; 11(7): 3121-34.
Sykaras AG, Pergaris A, Theocharis S. Challenging, accurate and feasible: CAF-1 as a tumour proliferation marker of diagnostic and prognostic value. Cancers. 2021 May; 13(11): 2575. doi: 10.3390/cancers13112575.
Juríková M, Danihel Ľ, Polák Š, Varga I. Ki67, PCNA, and MCM proteins: Markers of proliferation in the diagnosis of breast cancer. Acta Histochemica. 2016 Jun; 118(5): 544-52. doi: 10.1016/j.acthis.2016.05.002.
Pinzi L and Rastelli G. Molecular docking: shifting paradigms in drug discovery. International Journal of Molecular Sciences. 2019 Sep; 20(18): 4331. doi: 10.3390/ijms20184331.
Khan M, Maryam A, Qazi JI, Ma T. Targeting apoptosis and multiple signaling pathways with icariside II in cancer cells. International Journal of Biological Sciences. 2015 Jul; 11(9): 1100. doi: 10.7150/ijbs.11595.
Wang G and Zhu W. Molecular docking for drug discovery and development: a widely used approach but far from perfect. Future Medicinal Chemistry. 2016 Sep; 8(14): 1707-10. doi: 10.4155/fmc-2016-0143.
Paço A, Brás T, Santos JO, Sampaio P, Gomes AC, Duarte MF et al. Anti-inflammatory and immunoregulatory action of sesquiterpene lactones. Molecules. 2022 Feb; 27(3): 1142. doi: 10.3390/molecules27031142.
Fan J, Fu A, Zhang L. Progress in molecular docking. Quantitative Biology. 2019 Jun; 7: 83-9. doi: 10.1007/s40484-019-0172-y.
Stanzione F, Giangreco I, Cole JC. Use of molecular docking computational tools in drug discovery. Progress in Medicinal Chemistry. 2021 Jan; 60: 273-343. doi: 10.1016/bs.pmch.2021.01.004.
Choudhary MI, Shaikh M, tul-Wahab A, ur-Rahman A. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. Plos One. 2020 Jul; 15(7): e0235030. doi: 10.1371/journal.pone.0235030.
Kar S and Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opinion on Drug Discovery. 2020 Dec; 15(12): 1473-87. doi: 10.1080/17460441.2020.1798926.
Beck TC, Springs K, Morningstar JE, Mills C, Stoddard A, Guo L et al. Application of Pharmacokinetic Prediction Platforms in the Design of Optimized Anti-Cancer Drugs. Molecules. 2022 Jun; 27(12): 3678. doi: 10.3390/molecules27123678.
Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug discovery today: Technologies. 2004 Dec; 1(4): 337-41. doi: 10.1016/j.ddtec.2004.11.007.
Aliarab A, Abroon S, Rasmi Y, Aziz SG. Application of sesquiterpene lactone: A new promising way for cancer therapy based on anticancer activity. Biomedicine & Pharmacotherapy. 2018 Oct; 106: 239-46. doi: 10.1016/j.biopha.2018.06.131.
He W, Lai R, Lin Q, Huang Y, Wang L. Arglabin is a plant sesquiterpene lactone that exerts potent anticancer effects on human oral squamous cancer cells via mitochondrial apoptosis and downregulation of the mTOR/PI3K/Akt signaling pathway to inhibit tumor growth in vivo. Journal of Buon. 2018 Nov; 23(6): 1679-85.
Huang H, Yi J, Park S, Zhang H, Kim E, Park S et al. Costunolide suppresses melanoma growth via the AKT/mTOR pathway in vitro and in vivo. American Journal of Cancer Research. 2021; 11(4): 1410 –1427.
Tang X, Ding Q, Chen C, Chen F, Zhou X, Hong CJ et al. Micheliolide inhibits gastric cancer growth in vitro and in vivo via blockade of the IL-6/STAT3 pathway. Die Pharmazie-An International Journal of Pharmaceutical Sciences. 2019 Mar; 74(3): 175-8. doi: 10.1691/ph.2019.8816.
Shultz MD. Two decades under the influence of the rule of five and the changing properties of approved oral drugs: miniperspective. Journal of Medicinal Chemistry. 2018 Sep; 62(4): 1701-14. doi: 10.1021/acs.jmedchem.8b00686.
Kuang Y, Shen W, Ma X, Wang Z, Xu R, Rao Q et al. In silico identiïcation of natural compounds against SARS-CoV-2 main protease from Chinese Herbal Medicines. Future Science OA. 2023 May; 9(7): FSO873. doi: 10.2144/fsoa-2023-0055.
Nguyen TT, Duong VA, Maeng HJ. Pharmaceutical formulations with P-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability. Pharmaceutics. 2021 Jul; 13(7): 1103. doi: 10.3390/pharmaceutics13071103.
Llorach-Pares L, Nonell-Canals A, Sanchez-Martinez M, Avila C. Computer-aided drug design applied to marine drug discovery: Meridianins as Alzheimer's disease therapeutic agents. Marine Drugs. 2017 Nov; 15(12): 366. doi: 10.3390/md15120366.
Dharmasaputra A and Rasyida AU. Azasterol Inhibition and Pharmacokinetic Effects on Thymidylate Synthase-Dihydrofolate Reductase from T. gondii: In Silico Study. Pharmacognosy Journal. 2022; 14(3). doi: 10.5530/pj.2022.14.73.
Wahyuningsih D, Purnomo Y, Tilaqza A. In Silico study of Pulutan (Urena lobata) leaf extract as anti-inflammation and their ADME prediction. Journal of Tropical Pharmacy and Chemistry. 2022 Jun; 6(1): 30-7. doi: 10.25026/jtpc.v6i1.323.
Muhammad S, Hassan SH, Al-Sehemi AG, Shakir HA, Khan M, Irfan M et al. Exploring the new potential antiviral constituents of Moringa oliefera for SARS COV-2 pathogenesis: An in silico molecular docking and dynamic studies. Chemical Physics Letters. 2021 Mar; 767: 138379. doi: 10.1016/j.cplett.2021.138379.
Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Current Drug Metabolism. 2008 May; 9(4): 310-22. doi: 10.2174/138920008784220664.
Yousaf Z, Zaman A, Ali M, Khan M, Ara C, Shakir HA et al. Sesquiterpene Lactones as Potential G1/S Phase Cell Cycle Inhibitors: A Molecular Docking Study: Sesquiterpene Lactones as Potential Cell Cycle Inhibitors. Pakistan BioMedical Journal. 2023 Aug; 6(8): 30-6. doi: 10.54393/pbmj.v6i08.925.
Zaman A, Yousaf Z, Gul S, Ali M, Khan M. Sesquiterpene Lactones as Potential Cyclin B1/CDK1 Complex Inhibitors: Sesquiterpene Lactones as Potential Cyclin B1/CDK1. Futuristic Biotechnology. 2023 Jun; 3(1): 19-24. doi: 10.54393/fbt.v3i01.38.
Wu M, Han J, Liu Z, Zhang Y, Huang C, Li J et al. Identification of novel CDK 9 inhibitors based on virtual screening, molecular dynamics simulation, and biological evaluation. Life Sciences. 2020 Oct; 258: 118228. doi: 10.1016/j.lfs.2020.118228.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Futuristic Biotechnology
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments editor@fbtjournal.com